Calithera Biosciences (Calithera Biosciences) Days Sales Outstanding : 0.00 (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Days Sales Outstanding?

Calithera Biosciences's average Accounts Receivable for the three months ended in Dec. 2022 was $0.00 Mil. Calithera Biosciences's Revenue for the three months ended in Dec. 2022 was $0.00 Mil.

The historical rank and industry rank for Calithera Biosciences's Days Sales Outstanding or its related term are showing as below:

CALA's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 71.97
* Ranked among companies with meaningful Days Sales Outstanding only.

Calithera Biosciences's Days Sales Outstanding stayed the same from Dec. 2021 (0.00) to Dec. 2022 (0.00).

Calithera Biosciences Days Sales Outstanding Historical Data

The historical data trend for Calithera Biosciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Days Sales Outstanding Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

25.74

57.69

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Calithera Biosciences's Days Sales Outstanding

For the Biotechnology subindustry, Calithera Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calithera Biosciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Days Sales Outstanding falls into.

Calithera Biosciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Calithera Biosciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Calithera Biosciences's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding (Q: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2022 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Calithera Biosciences (OTCPK:CALA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Calithera Biosciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Calithera Biosciences (Calithera Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Executives

Deepika Pakianathan	director, 10 percent owner	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford	officer: SR. VP, CLINICAL DEVELOPMENT	CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux	director, officer: PRESIDENT AND CEO	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux	officer: SR. VP, DEVELOPMENT	CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose	officer: CHIEF MEDICAL OFFICER	343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc	10 percent owner	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong	officer: VP, FINANCE	343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104